Nothing Special   »   [go: up one dir, main page]

CR20180508A - NUEVA INMUNOTERAPIA CONTRA DIVERSOS TUMORES COMO EL CÁNCER DE PULMÓN, INCLUIDO EL CARCINOMA DE PÚLMON AMICROCÍTICO (NSCLC) (Divisional 2016-0018) - Google Patents

NUEVA INMUNOTERAPIA CONTRA DIVERSOS TUMORES COMO EL CÁNCER DE PULMÓN, INCLUIDO EL CARCINOMA DE PÚLMON AMICROCÍTICO (NSCLC) (Divisional 2016-0018)

Info

Publication number
CR20180508A
CR20180508A CR20180508A CR20180508A CR20180508A CR 20180508 A CR20180508 A CR 20180508A CR 20180508 A CR20180508 A CR 20180508A CR 20180508 A CR20180508 A CR 20180508A CR 20180508 A CR20180508 A CR 20180508A
Authority
CR
Costa Rica
Prior art keywords
relates
present
cancer
amicrocítico
pulmon
Prior art date
Application number
CR20180508A
Other languages
English (en)
Inventor
Toni Weinschenk
Steffen Walter
Colette Song
Jens Fritsche
Harpreet Singh
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52460698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20180508(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1313987.8A external-priority patent/GB201313987D0/en
Priority claimed from GBGB1403297.3A external-priority patent/GB201403297D0/en
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of CR20180508A publication Critical patent/CR20180508A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24065—Macrophage elastase (3.4.24.65), i.e. metalloelastase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a péptidos, ácidos nucleicos y células para la utilización en métodos inmunoterapéuticos. En concreto, la presente invención se refiere a la inmunoterapia contra el cáncer. La presente invención se refiere, además, a epítopos peptídicos de linfocitos T citotóxicos (CTL) asociados a tumor, solos o en combinación con otros péptidos asociados a tumor que sirven como principios activos farmacéuticos de composiciones vacunales que estimulan respuestas inmunitarias antitumorales. La presente invención se refiere a más de 70 nuevas secuencias peptídicas y sus variantes derivadas de moléculas HLA de clase I y clase II de células tumorales humanas que pueden ser utilizadas en composiciones vacunales para desencadenar respuestas inmunitarias antitumorales.
CR20180508A 2013-08-05 2014-08-04 NUEVA INMUNOTERAPIA CONTRA DIVERSOS TUMORES COMO EL CÁNCER DE PULMÓN, INCLUIDO EL CARCINOMA DE PÚLMON AMICROCÍTICO (NSCLC) (Divisional 2016-0018) CR20180508A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361862213P 2013-08-05 2013-08-05
GBGB1313987.8A GB201313987D0 (en) 2013-08-05 2013-08-05 Novel immunotherapy against several tumors, such as lung cancer including NSCLC
GBGB1403297.3A GB201403297D0 (en) 2014-02-25 2014-02-25 Novel immunotherapy against several tumors, such as lung cancer, including NSCLC
PCT/EP2014/066755 WO2015018805A1 (en) 2013-08-05 2014-08-04 Novel immunotherapy against several tumors, such as lung cancer, including nsclc

Publications (1)

Publication Number Publication Date
CR20180508A true CR20180508A (es) 2019-02-27

Family

ID=52460698

Family Applications (4)

Application Number Title Priority Date Filing Date
CR20180508A CR20180508A (es) 2013-08-05 2014-08-04 NUEVA INMUNOTERAPIA CONTRA DIVERSOS TUMORES COMO EL CÁNCER DE PULMÓN, INCLUIDO EL CARCINOMA DE PÚLMON AMICROCÍTICO (NSCLC) (Divisional 2016-0018)
CR20200139A CR20200139A (es) 2013-08-05 2014-08-04 Nueva inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido el carcinoma de pulmón amicrocítico (nsclc) (divisional 2016-0018)
CR20210464A CR20210464A (es) 2013-08-05 2014-08-04 Nueva inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido en carcinoma del pulmón amicrocítico (nsclc)
CR20160018A CR20160018A (es) 2013-08-05 2016-01-08 Nueva inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido el carcinoma de pulmón amicrocítico (nsclc)

Family Applications After (3)

Application Number Title Priority Date Filing Date
CR20200139A CR20200139A (es) 2013-08-05 2014-08-04 Nueva inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido el carcinoma de pulmón amicrocítico (nsclc) (divisional 2016-0018)
CR20210464A CR20210464A (es) 2013-08-05 2014-08-04 Nueva inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido en carcinoma del pulmón amicrocítico (nsclc)
CR20160018A CR20160018A (es) 2013-08-05 2016-01-08 Nueva inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido el carcinoma de pulmón amicrocítico (nsclc)

Country Status (29)

Country Link
US (3) US20160168200A1 (es)
EP (10) EP3578196A1 (es)
JP (1) JP2016527293A (es)
KR (9) KR102098329B1 (es)
CN (1) CN105377290B (es)
AU (10) AU2014304544B2 (es)
BR (1) BR112016000810A2 (es)
CA (4) CA2912500C (es)
CL (1) CL2016000227A1 (es)
CR (4) CR20180508A (es)
DK (2) DK3456339T3 (es)
EA (1) EA035362B1 (es)
ES (1) ES2764406T3 (es)
HK (1) HK1222121A1 (es)
HU (1) HUE047079T2 (es)
IL (1) IL243788B (es)
LT (1) LT3030255T (es)
MX (1) MX2016001426A (es)
NZ (2) NZ733168A (es)
PE (3) PE20160717A1 (es)
PH (1) PH12015502638A1 (es)
PL (1) PL3030255T3 (es)
PT (1) PT3030255T (es)
RS (1) RS59861B1 (es)
SG (4) SG11201510580UA (es)
SI (1) SI3030255T1 (es)
TW (10) TWI714869B (es)
UA (1) UA122661C2 (es)
WO (1) WO2015018805A1 (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
SI3456339T1 (sl) 2013-08-05 2022-01-31 Immatics Biotechnologies Gmbh Nova imunoterapija proti več tumorjem, kot je pljučni rak, vključno z nedrobnoceličnim pljučnim rakom
EP3092049A1 (en) 2014-01-08 2016-11-16 Flodesign Sonics Inc. Acoustophoresis device with dual acoustophoretic chamber
GB201504502D0 (en) * 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
KR20240151873A (ko) * 2015-03-17 2024-10-18 이매틱스 바이오테크놀로지스 게엠베하 췌장암 및 기타 암에 대한 면역요법에서의 사용을 위한 펩티드 및 펩티드의 조합
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
KR20220167337A (ko) 2015-03-27 2022-12-20 이매틱스 바이오테크놀로지스 게엠베하 다양한 종양에 대한 면역요법에서의 사용을 위한 펩티드 및 펩티드의 조합
TWI772927B (zh) * 2015-03-31 2022-08-01 德商英麥提克生物技術股份有限公司 用於腎細胞癌(rcc)免疫治療的新型肽和肽組合物和支架
GB201505585D0 (en) * 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
GB201507719D0 (en) * 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
CR20230131A (es) * 2015-05-06 2023-06-23 Immatics Biotechnologies Gmbh NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS Y DE SOPORTES PARA LA INMUNOTERAPIA CONTRA EL CARCINOMA COLORRECTAL Y OTROS TIPOS DE CÁNCER (Divisional Exp. 2017-0497)
PE20180670A1 (es) * 2015-05-20 2018-04-19 Broad Inst Inc Neoantigenos compartidos
EA201792531A1 (ru) * 2015-06-19 2018-05-31 Имматикс Байотекнолоджиз Гмбх Новые пептиды и комбинации пептидов для применения в иммунотерапии и способы получения каркасов для применения при лечении рака поджелудочной железы и других видов рака
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
PE20230321A1 (es) 2015-07-01 2023-02-22 Immatics Biotechnologies Gmbh Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer
HUE052628T2 (hu) * 2015-07-06 2021-05-28 Immatics Biotechnologies Gmbh Új peptidek és peptidkombináció a nyelõcsõrák és más ráktípusok elleni immunterápiában történõ használatra
GB201512369D0 (en) * 2015-07-15 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
US20170136108A1 (en) 2015-08-28 2017-05-18 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
IL292864A (en) * 2015-08-28 2022-07-01 Immatics Biotechnologies Gmbh New peptides and a combination of peptides and supports for use in immunotherapy in certain types of cancer
GB201517538D0 (en) * 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
MY198087A (en) 2015-10-05 2023-07-31 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
KR20170049024A (ko) * 2015-10-28 2017-05-10 숙명여자대학교산학협력단 ANKs1a 단백질 발현 또는 활성 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 조성물 및 이의 스크리닝 방법
GB201521746D0 (en) 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
PE20230343A1 (es) 2015-12-11 2023-03-01 Immatics Biotechnologies Gmbh Peptidos que estimulan respuestas inmunitarias antitumorales
US10383896B2 (en) 2015-12-11 2019-08-20 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against various cancers
GB201521894D0 (en) 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
EP4299136A3 (en) 2015-12-16 2024-02-14 Gritstone bio, Inc. Neoantigen identification, manufacture, and use
GB201522667D0 (en) * 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
SG10202111399YA (en) 2015-12-22 2021-11-29 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201602918D0 (en) * 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
GB201603987D0 (en) * 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
GB201604458D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
KR20220097524A (ko) * 2016-04-06 2022-07-07 이매틱스 바이오테크놀로지스 게엠베하 Aml 및 다른 암에 대한 면역요법에 사용하기 위한 펩티드 및 펩티드의 조합
MA43477A1 (fr) * 2016-04-21 2019-05-31 Immatics Biotechnologies Gmbh Immunothérapie contre le mélanome et d'autres cancers
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
US10868749B2 (en) * 2016-07-26 2020-12-15 Motorola Mobility Llc Method and apparatus for discovering neighborhood awareness networking devices based on presence
SI3500593T1 (sl) * 2016-08-17 2021-12-31 Immatics Biotechnologies Gmbh T-celični receptorji in imunska terapija z njihovo uporabo
TWI796299B (zh) * 2016-08-26 2023-03-21 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
EP3516081A4 (en) * 2016-09-23 2020-07-29 Memorial Sloan Kettering Cancer Center DETERMINANTS OF CANCER REACTION TO IMMUNOTHERAPY
CN110139875B (zh) * 2016-09-30 2023-03-03 武汉华大吉诺因生物科技有限公司 Col14a1衍生的肿瘤抗原多肽及其应用
WO2018102613A2 (en) * 2016-12-01 2018-06-07 Nantomics, Llc Tumor antigenicity processing and presentation
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
WO2018170313A1 (en) * 2017-03-16 2018-09-20 Advaxis, Inc. Methods and compositions for increasing efficacy of vaccines
SG10202100324YA (en) * 2017-04-10 2021-02-25 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
CN117946213A (zh) * 2017-04-28 2024-04-30 中山医学大学 治疗癌症的肽
WO2018208856A1 (en) 2017-05-08 2018-11-15 Gritstone Oncology, Inc. Alphavirus neoantigen vectors
CR20210167A (es) 2017-07-07 2021-05-24 Immatics Biotechnologies Gmbh Nuevos péptidos y nuevas combinaciones de péptidos para el uso de la inmunoterapia contra el cáncer de pulmón, incluyendo el nsclc, el sclc y otros cánceres
WO2019007974A1 (en) 2017-07-07 2019-01-10 Immatics Biotechnologies Gmbh NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS
KR20200087143A (ko) 2017-10-10 2020-07-20 그릿스톤 온콜로지, 인코포레이티드 핫스팟을 이용한 신생항원 동정
GB201717578D0 (en) * 2017-10-26 2017-12-13 Univ College Cardiff Consultants Ltd Novel T-cell receptor
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
AU2018385759B2 (en) 2017-12-14 2021-10-21 Flodesign Sonics, Inc. Acoustic transducer driver and controller
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202016131A (zh) * 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
CA3099644A1 (en) * 2018-05-23 2019-11-28 Gritstone Oncology, Inc. Shared antigens
CN110627895B (zh) * 2018-06-25 2021-03-23 北京大学 肺癌特异性tcr及其分析技术和应用
US10925947B2 (en) * 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
EP3946440A4 (en) * 2019-04-02 2023-04-19 The General Hospital Corporation METHOD OF INCREASING T-CELL REGENERATION
SG11202113187WA (en) 2019-05-30 2021-12-30 Gritstone Bio Inc Modified adenoviruses
WO2021016109A1 (en) * 2019-07-19 2021-01-28 The Regents Of The University Of California T-cell receptors and methods of use thereof
CN111020024A (zh) * 2019-12-05 2020-04-17 复旦大学附属眼耳鼻喉科医院 Tlr9的应用
CN111808908A (zh) * 2020-06-18 2020-10-23 华中科技大学同济医学院附属协和医院 一种促脑胶质瘤耐药的gaMSCs亚群的检测方法
CN116583295A (zh) * 2020-12-07 2023-08-11 印地安纳大学理事会 使用白术内酯i使癌细胞对免疫攻击敏感的方法
CN113881707B (zh) * 2021-10-25 2023-07-14 中国人民解放军军事科学院军事医学研究院 调控脐带间充质干细胞免疫抑制作用的产品、方法及用途
CN113969264B (zh) * 2021-11-29 2023-12-08 中南大学 Cog5基因敲除的人胚胎干细胞系、构建方法及应用
CN115125203B (zh) * 2022-07-08 2023-10-27 珠海贝索细胞科学技术有限公司 一种Th2细胞体外培养方法

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8212000B2 (en) * 1970-02-11 2012-07-03 Immatics Biotechnologies Gmbh Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
DD147855A5 (de) 1978-12-22 1981-04-22 Biogen Nv Verfahren zur erzeugung mindestens eines hbv-antigenwirkung aufweisenden polypeptids
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
EP0701571B1 (en) 1993-06-03 1997-08-20 Therapeutic Antibodies Inc. Antibody fragments in therapy
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
IL151860A0 (en) 2000-03-27 2003-04-10 Technion Res & Dev Foundation Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
AU7524601A (en) 2000-06-05 2001-12-17 Sunol Molecular Corp T cell receptor fusions and conjugates and methods of use thereof
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
JP2005500059A (ja) * 2001-08-13 2005-01-06 ダナ−ファーバー キャンサー インスティテュート インク． ペリオスチンに基づく診断アッセイ法
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US20030223994A1 (en) 2002-02-20 2003-12-04 Hoogenboom Henricus Renerus Jacobus Mattheus MHC-peptide complex binding ligands
WO2004018633A2 (en) * 2002-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services Abca13 nucleic acids and proteins, and uses thereof
WO2004033685A1 (en) 2002-10-09 2004-04-22 Avidex Ltd Single chain recombinant t cell receptors
EP1558643B1 (en) 2002-11-09 2009-05-27 Immunocore Ltd. T cell receptor display
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
KR100535326B1 (ko) * 2004-01-20 2005-12-09 한국생명공학연구원 줄기 세포로부터 자연살해 세포로의 분화 조절용 유전자를유효성분으로 포함하는 분화 조절제
CN104072614B (zh) 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
PL1806359T3 (pl) 2005-09-05 2010-08-31 Immatics Biotechnologies Gmbh Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami ludzkich antygenów leukocytarnych (HLA) klasy II
EP1760089B1 (en) * 2005-09-05 2009-08-19 Immatics Biotechnologies GmbH Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine
WO2007096142A2 (en) * 2006-02-22 2007-08-30 Philogen Spa Vascular tumor markers
US20080107668A1 (en) * 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
SI2567707T1 (sl) * 2007-07-27 2017-01-31 Immatics Biotechnologies Gmbh Sestava s tumorjem povezanih peptidov in zadevnih cepiv proti raku
WO2009036246A2 (en) * 2007-09-14 2009-03-19 Immunotope, Inc. Immunogens that induce cytotoxic t-lymphocytes and their use in prevention, treatment, and diagnosis of cancer
AU2008320987B2 (en) 2007-11-13 2014-04-17 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against TL1A
US7996174B2 (en) * 2007-12-18 2011-08-09 Teradyne, Inc. Disk drive testing
WO2009111507A1 (en) * 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 12 binding proteins
EP2268838A1 (en) * 2008-04-11 2011-01-05 China Synthetic Rubber Corporation Methods, agents and kits for the detection of cancer
PT2113253E (pt) 2008-04-30 2010-06-15 Immatics Biotechnologies Gmbh Formulações novas de peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antígeno leucocitário humano (hla) para vacinas
TWI526219B (zh) * 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
CN102137874B (zh) * 2008-08-29 2015-02-18 西福根有限公司 抗表皮生长因子受体的重组抗体组合物
ES2536465T3 (es) * 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
WO2010045388A2 (en) * 2008-10-14 2010-04-22 Dyax Corp. Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis
EP2221063A1 (en) * 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
CN102459646B (zh) * 2009-05-15 2016-08-10 环太平洋生物技术有限公司 胃癌的检测标志物
US20110033516A1 (en) * 2009-08-06 2011-02-10 Medical University Of South Carolina Methods and compositions for bone healing by periostin
US8281223B2 (en) 2009-08-07 2012-10-02 Via Technologies, Inc. Detection of fuse re-growth in a microprocessor
WO2011050270A2 (en) 2009-10-23 2011-04-28 Tranzyme Pharma, Inc. Macrocyclic inhibitors of serine protease enzymes
TWI485245B (zh) * 2010-01-25 2015-05-21 Oncotherapy Science Inc 經修飾之ｍｅｌｋ胜肽及含此胜肽之疫苗
KR101378919B1 (ko) * 2010-01-28 2014-04-14 포항공과대학교 산학협력단 혈액으로부터 직접 폐암 진단 및 폐암의 서브타입 진단이 가능한 마커를 선별하는 시스템 생물학적 방법 및 이로부터 선별된 혈액으로부터 직접 폐암 진단 및 폐암 서브타입 진단이 가능한 마커
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201006360D0 (en) * 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
GB201009222D0 (en) * 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
US20140170168A1 (en) 2010-10-26 2014-06-19 Yoram Reiter Antibodies which bind soluble t-cell receptor ligands
US9028810B2 (en) * 2010-12-20 2015-05-12 Ajou University Industry—Academic Cooperations Foundatin Composition for inducing migration of neural stem cells containing periostin as effective ingredient
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
GB201319446D0 (en) * 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors

Also Published As

Publication number Publication date
TW202041519A (zh) 2020-11-16
UA122661C2 (uk) 2020-12-28
US20170202937A1 (en) 2017-07-20
TW202041522A (zh) 2020-11-16
DK3456339T3 (da) 2021-12-06
PE20201284A1 (es) 2020-11-24
RS59861B1 (sr) 2020-03-31
NZ733168A (en) 2020-04-24
EP3616711A1 (en) 2020-03-04
KR20180107295A (ko) 2018-10-01
KR20200078681A (ko) 2020-07-01
AU2020220043B2 (en) 2021-11-25
AU2020220040B2 (en) 2021-11-25
KR20210008169A (ko) 2021-01-20
HUE047079T2 (hu) 2020-04-28
SG10201802399WA (en) 2018-04-27
CR20200139A (es) 2020-09-02
TW201506043A (zh) 2015-02-16
AU2020220043A1 (en) 2020-09-03
TWI777196B (zh) 2022-09-11
KR102213556B1 (ko) 2021-02-05
US9943579B2 (en) 2018-04-17
TW202041516A (zh) 2020-11-16
EP3616708A1 (en) 2020-03-04
SG10202002612PA (en) 2020-05-28
TWI776192B (zh) 2022-09-01
TWI777197B (zh) 2022-09-11
US10071148B2 (en) 2018-09-11
EA201690016A1 (ru) 2016-05-31
AU2014304544B2 (en) 2017-10-26
SG11201510580UA (en) 2016-02-26
EP3616710A1 (en) 2020-03-04
CA3073256A1 (en) 2015-02-12
TWI775117B (zh) 2022-08-21
PT3030255T (pt) 2020-01-15
AU2020220042B2 (en) 2021-11-25
TWI777195B (zh) 2022-09-11
AU2018200389A1 (en) 2018-02-08
EP3613427A1 (en) 2020-02-26
AU2020220042A1 (en) 2020-09-03
AU2018200389B2 (en) 2020-07-16
US20170319675A1 (en) 2017-11-09
DK3030255T3 (da) 2020-01-20
KR20200122418A (ko) 2020-10-27
AU2020220039B2 (en) 2021-05-20
KR20200122417A (ko) 2020-10-27
AU2020220038B2 (en) 2021-11-25
TWI819228B (zh) 2023-10-21
NZ714163A (en) 2017-07-28
PE20181538A1 (es) 2018-09-26
EP3030255A1 (en) 2016-06-15
CR20160018A (es) 2016-06-08
KR102213554B1 (ko) 2021-02-05
TWI636065B (zh) 2018-09-21
CR20210464A (es) 2021-10-26
EP3616712A1 (en) 2020-03-04
AU2020220045B2 (en) 2021-11-25
AU2020220044A1 (en) 2020-09-03
CL2016000227A1 (es) 2016-08-05
CA2912500C (en) 2021-08-24
JP2016527293A (ja) 2016-09-08
EP3456339A2 (en) 2019-03-20
KR20200122419A (ko) 2020-10-27
KR20160038889A (ko) 2016-04-07
BR112016000810A2 (pt) 2017-12-12
CA3073394A1 (en) 2015-02-12
MX2016001426A (es) 2016-05-05
PE20160717A1 (es) 2016-07-21
AU2014304544A1 (en) 2015-12-03
CA2912500A1 (en) 2015-02-12
CA3020939A1 (en) 2015-02-12
AU2020220044B2 (en) 2021-11-25
TWI777194B (zh) 2022-09-11
KR102217680B1 (ko) 2021-02-18
SI3030255T1 (sl) 2020-02-28
CN105377290B (zh) 2019-09-03
KR102098327B1 (ko) 2020-04-08
AU2020220040A1 (en) 2020-09-03
KR102317816B1 (ko) 2021-10-26
KR20180105754A (ko) 2018-09-28
SG10202002608WA (en) 2020-04-29
TW202041518A (zh) 2020-11-16
TW202041520A (zh) 2020-11-16
HK1222121A1 (zh) 2017-06-23
EP3030255B1 (en) 2019-10-09
IL243788A0 (en) 2016-04-21
ES2764406T3 (es) 2020-06-03
TWI714869B (zh) 2021-01-01
PH12015502638A1 (en) 2016-03-07
LT3030255T (lt) 2020-01-27
TW202041517A (zh) 2020-11-16
EP3616709A1 (en) 2020-03-04
PL3030255T3 (pl) 2020-05-18
KR102213551B1 (ko) 2021-02-05
KR102213552B1 (ko) 2021-02-05
EP3456339B1 (en) 2021-10-20
IL243788B (en) 2019-10-31
TWI777198B (zh) 2022-09-11
AU2020220041A1 (en) 2020-09-03
EA035362B1 (ru) 2020-06-02
AU2020220041B2 (en) 2021-11-25
KR102098329B1 (ko) 2020-04-09
CA3020939C (en) 2023-01-03
EP3616707A1 (en) 2020-03-04
WO2015018805A1 (en) 2015-02-12
EP3456339A3 (en) 2019-03-27
KR20200123266A (ko) 2020-10-28
US20160168200A1 (en) 2016-06-16
TW201900669A (zh) 2019-01-01
AU2020220045A1 (en) 2020-09-03
AU2020220038A1 (en) 2020-09-03
AU2020220039A1 (en) 2020-09-03
CN105377290A (zh) 2016-03-02
EP3578196A1 (en) 2019-12-11
KR102211542B1 (ko) 2021-02-02
TW202041515A (zh) 2020-11-16
TW202041521A (zh) 2020-11-16

Similar Documents

Publication Publication Date Title
CR20180508A (es) NUEVA INMUNOTERAPIA CONTRA DIVERSOS TUMORES COMO EL CÁNCER DE PULMÓN, INCLUIDO EL CARCINOMA DE PÚLMON AMICROCÍTICO (NSCLC) (Divisional 2016-0018)
CU20160060A7 (es) Péptidos, ácidos nucleicos y células, útiles en la inmunoterapia personalizada contra diversos tumores cerebrales y neuronales
PH12021551208A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
CR20160531A (es) Inmunoterapia novedosa contra varios tumores de la sangre, como la leucemia mielógena aguda (lma)
EA202091233A3 (ru) Новые способы иммунотерапии нескольких видов опухолей, в том числе рака желудочно-кишечного тракта и рака желудка
MX2019013163A (es) Inmunoterapia novedosa contra varios tumores de la sangre, con la leucemia mielogena aguda (lma).
AR118181A2 (es) Inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido el carcinoma de pulmón amicrocítico (nsclc)
AR113131A2 (es) Inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido el carcinoma de pulmón amicrocítico (nsclc)
MY194653A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
MY194244A (en) Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including Nsclc
MY194241A (en) Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including NSCLC
MY193910A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
EA202090822A2 (ru) Новый метод иммунотерапии нескольких видов опухолей, таких как рак легкого, включая нмрл
MX2019013161A (es) Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales.
AR100926A1 (es) Inmunoterapia contra varios tumores de la sangre, en particular contra la leucemia linfoide crónica (llc)